股票代码：300016 股票简称：北陆药业 公告编号：2025-053 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于2025年5月23日在巨 潮资讯网发布了《关于召开2025年第二次临时股东大会的通知》，为进一步保 护投资者的合法权益，方便公司股东行使股东大会表决权，现将股东大会的有 关事项提示如下： 一、召开会议的基本情况 过了《关于召开2025年第二次临时股东大会的议案》，本次股东大会会议的召 开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》等规定。 （1）现场会议召开时间为：2025年6月9日（星期一）下午14：00 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具 体时间为2025年6月9日9：15—9：25、9：30—11：30、13：00—15：00；通 过深圳证券交易所互联网投票系统投票的时间为2025年6月9日上午9：15至下 午15：00期间的任意时间。 （1）现场投票：包括本人出席及通过填写授权 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-053 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于2025年5月23日在巨 潮资讯网发布了《关于召开2025年第二次临时股东大会的通知》，为进一步保 护投资者的合法权益，方便公司股东行使股东大会表决权，现将股东大会的有 关事项提示如下： 一、召开会议的基本情况 1、股东大会届次：2025年第二次临时股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：公司第八届董事会第二十七次会议审议通 过了《关于召开2025年第二次临时股东大会的议案》，本次股东大会会议的召 开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议召开的日期和时间： （1）现场会议召开时间为：2025年6月9日（星期一）下午14：00 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具 体时间为2025年6月9日 ...

Group 1 - Aike Technology (688092.SH) shareholders plan to reduce their holdings by up to 826,906 shares, accounting for 1.00% of the total share capital within three months after 15 trading days from the announcement [1] - Aike Cyber (688719.SH) executives plan to reduce their holdings by up to 2.1927% of the total share capital, totaling 2,530,000 shares within three months after 15 trading days from the announcement [1] - Anpeilong (301413.SZ) shareholders plan to reduce their holdings by up to 2,952,058 shares, representing 3% of the total share capital [1] Group 2 - Chaohongji (002345.SZ) shareholders plan to reduce their holdings by up to 26,655,380 shares, accounting for 3% of the total share capital within three months after 15 trading days from the announcement [2] - Chunguang Technology (603657.SH) plans to reduce its holdings by up to 1,000,000 shares, representing 0.73% of the total share capital [2] - Dahongli (300865.SZ) controlling shareholder plans to reduce his holdings by 136,150 shares, accounting for 1.4230% of the total share capital [2] Group 3 - Electric Link Technology (300679.SZ) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 15,000 to 78,000 shares [2] - Guangge Technology (688450.SH) shareholders plan to reduce their holdings by a total of 990,000 shares, representing 1.50% of the total share capital [2] - Guorui Technology (300600.SZ) shareholders plan to reduce their holdings by 8,827,034 shares, accounting for 3% of the total share capital [3] Group 4 - Hailier (603639.SH) shareholders plan to reduce their holdings by up to 1,200,000 shares, representing 1% of the total share capital [3] - Haotong Technology (301026.SZ) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 20,965 to 47,250 shares [3] - Huamao Logistics (603128.SH) executives have reduced their holdings by 272,000 shares, while other executives did not reduce their holdings [3] Group 5 - Jiamei Packaging (002969.SZ) shareholders plan to reduce their holdings by a total of 9,483,239 shares, accounting for 1.00% of the total share capital [4] - Jiangsu Boyun (301003.SZ) shareholders plan to reduce their holdings by up to 971,333 shares through centralized bidding and 1,942,666 shares through block trading [4] - Jinchicken Co., Ltd. (300798.SZ) shareholders plan to reduce their holdings by 14,000,000 shares, representing 2.99% of the total share capital [4] Group 6 - Jingfang Technology (603005.SH) shareholders plan to reduce their holdings by up to 13,043,400 shares, accounting for 2% of the total share capital [5] - Jingjin Electric (688280.SH) shareholders plan to reduce their holdings through centralized bidding or block trading [5] - Kolon New Materials (920098) shareholders have not implemented reductions, while another shareholder reduced holdings by 651,667 shares, representing 0.8014% of the total share capital [5] Group 7 - Liangpinpuzi (603719.SH) shareholders plan to reduce their holdings by 4,010,000 shares, accounting for 1% of the total share capital [6] - Mike Audi (300341.SZ) executives plan to reduce their holdings by 546,350 shares, representing 0.11% of the total share capital [6] - Pinwa Food (300892.SZ) shareholders reduced their holdings by 711,300 shares, accounting for 0.72% of the total share capital [6] Group 8 - Qiu Le Seed Industry (831087.BJ) shareholders plan to reduce their holdings by up to 3,300,000 shares, representing no more than 1.9975% of the total share capital [6] - Qiu Tianwei (300939.SZ) shareholders reduced their holdings by 1,100,000 shares, accounting for 0.93% of the total share capital [6] - Rejing Bio (688068.SH) shareholders plan to reduce their holdings by 1,800,000 shares, representing 1.9416% of the total share capital [7] Group 9 - Saike Xide (688338.SH) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 250,000 to 235,000 shares [7] - Wancheng Group (300972.SZ) executives plan to reduce their holdings through centralized bidding [7] - Wentai Technology (600745.SH) shareholders plan to reduce their holdings by up to 24,891,577 shares through block trading and 12,445,788 shares through centralized bidding [7] Group 10 - Xiechuang Data (300857.SZ) executives plan to reduce their holdings by specified amounts, with individual reductions not exceeding 10,500 to 18,900 shares [8] - Xinhongze (002836.SZ) controlling shareholder reduced holdings by 1,895,300 shares, decreasing ownership from 63.74% to 62.91% [8] - Panda Dairy (300898.SZ) shareholders reduced their holdings by 884,470 shares, accounting for 0.7133% of the total share capital [8] Group 11 - Oat Technology (688312.SH) controlling shareholder plans to reduce holdings by up to 2,912,000 shares, representing no more than 2% of the total share capital [9] - Youningwei (301166.SZ) shareholders plan to reduce their holdings by 1,208,500 shares, accounting for 1.41% of the total share capital [9] - Yuhua Tian (300815.SZ) shareholders plan to reduce their holdings by up to 23,915,520 shares, representing no more than 6.00% of the total share capital [9] Group 12 - Zhangzidao (002069.SZ) shareholders plan to reduce their holdings by up to 7,111,000 shares, accounting for no more than 1% of the total share capital [9] - Zhishang Technology (301486.SZ) shareholders reduced their holdings by 1,245,300 shares, accounting for 0.9677% of the total share capital [10] - Zhongjing Electronics (002579.SZ) shareholders plan to reduce their holdings by up to 6,000,000 shares through centralized bidding or block trading [10]

股票代码：300016 股票简称：北陆药业 公告编号：2025-052 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 公司董事兼副总经理宗利女士保证向公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 北京北陆药业股份有限公司（以下简称"公司"）于2025年2月28日在巨 潮资讯网披露了《关于持股5%以上股东、董事兼高级管理人员减持股份的预 披露公告》(公告编号：2025-014)，持有公司股份163,200股（占公司总股本 诺、计划一致，本次减持计划已实施完毕。 三、备查文件 宗利女士出具的《关于股份减持计划实施情况说明》。 特此公告。 近日，公司收到宗利女士出具的《关于股份减持计划实施情况说明》。截 至本公告日，宗利女士通过集中竞价方式累计减持40,800股公司股份，占公司 总股本的0.0083%，本次减持计划已实施完毕。现将具体情况公告如下： 一、股东减持情况 | 股东 | 减持 | | | 减持均价 | | 减持股数 | | 减持数量占 | | --- | --- | --- | -- ...

近日，公司收到宗利女士出具的《关于股份减持计划实施情况说明》。截 至本公告日，宗利女士通过集中竞价方式累计减持40,800股公司股份，占公司 总股本的0.0083%，本次减持计划已实施完毕。现将具体情况公告如下： 1 北京北陆药业股份有限公司（以下简称"公司"）于2025年2月28日在巨 潮资讯网披露了《关于持股5%以上股东、董事兼高级管理人员减持股份的预 披露公告》(公告编号：2025-014)，持有公司股份163,200股（占公司总股本 0.0332%）的董事兼副总经理宗利女士计划自公告披露之日起15个交易日后的 3个月内，以集中竞价的方式减持不超过40,800股公司股份（占公司总股本 0.0083%）。 关于董事兼高级管理人员减持股份计划实施完毕的公告 公司董事兼副总经理宗利女士保证向公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 | 股票代码：300016 | 股票简称：北陆药业 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：123082 | 债券简称：北陆转债 ...

Group 1: Company Overview and Financial Performance - Beilu Pharmaceutical's contrast agent products generated sales revenue of 58,804.95 million yuan in 2024, representing a year-on-year growth of 9.87% [1] - The company achieved EU GMP and Brazil ANVISA GMP certifications for its production lines, supporting ongoing business growth [1] - The company plans to continue expanding its global market presence in 2025, focusing on steady growth in its contrast agent business [1] Group 2: Product Development and Innovation - The company has actively completed the bidding and registration processes for iodinated contrast agents, including Iohexol and Iopamidol [1] - In July 2024, the company received approval for Gadobutrol injection, which has been included in the national procurement list, enhancing market share and brand influence [1] Group 3: Medical Technology and Product Offerings - Yiwei Medical has launched three main products: - Yiwei-Brain Doctor, the first AI medical software for early Alzheimer's diagnosis, certified by both the National Medical Products Administration and CE [2] - Yiwei-Ruibrain, a comprehensive AI-assisted diagnosis platform for stroke, with dual certification from the National Medical Products Administration and FDA [2] - Yiwei-Digital Therapy, a cognitive assessment and rehabilitation product integrating eye-tracking and VR technologies [2] Group 4: Business Model and Market Strategy - Yiwei Medical focuses on precision diagnosis and treatment of brain diseases, offering a full-service model from screening to rehabilitation [3] - The company collaborates with health check institutions to provide a comprehensive "brain routine" health check package [3] - Yiwei Medical is exploring additional business models to expand market coverage and increase revenue streams [3] Group 5: Recent Developments in Partner Companies - Shihe Gene has made significant advancements in multi-cancer early screening technology, utilizing ultra-low depth whole genome sequencing and AI models [4] - The "Shihe Eagle Eye" product can screen for nine types of cancer with a single blood sample, significantly improving screening efficiency [4] - The product has received CE certification in the EU and breakthrough device designation from the FDA, outperforming international counterparts [4] Group 6: Industry Position and Competitive Advantage - Haichang Pharmaceutical is one of the few domestic companies with production capacity for iodinated contrast agent raw materials, with an annual output of 1,000 tons [5] - The recent approvals for Iopamidol and Iopromide raw materials enhance the company's competitive edge and product diversity [5]

截至6月3日收盘，创新药概念上涨3.38%，位居概念板块涨幅第7，板块内，173股上涨，华纳药厂、舒 泰神、冠昊生物等20%涨停，万邦德、千红制药、昂利康等涨停，诺思兰德、科兴制药、海特生物等涨 幅居前，分别上涨18.82%、14.97%、13.18%。跌幅居前的有*ST苏吴、海创药业、百利天恒等，分别下 跌4.78%、3.73%、2.87%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 4.23 | 特钢概念 | -0.93 | | 细胞免疫治疗 | 3.87 | 医疗废物处理 | -0.51 | | 重组蛋白 | 3.64 | 果指数 | -0.41 | | 足球概念 | 3.56 | 无线充电 | -0.39 | | 毛发医疗 | 3.51 | 光热发电 | -0.33 | | CRO概念 | 3.41 | 深圳国企改革 | -0.24 | | 创新药 | 3.38 | F5G概念 | -0.23 | | 培育钻石 | 3.11 | 租售同权 | -0.22 | | 仿制药一致性评价 ...

Core Viewpoint - The generic drug consistency evaluation concept has seen a notable increase in stock prices, with a rise of 3.08%, ranking it as the 9th highest among concept sectors as of June 3 [1][2]. Group 1: Stock Performance - Within the generic drug consistency evaluation sector, 116 stocks experienced gains, with notable performers including Huana Pharmaceutical and Beilu Pharmaceutical, both reaching a 20% limit up [1]. - Other significant gainers included Wantong Pharmaceutical (10.06%), Qianhong Pharmaceutical (10.05%), and Anglikang (10.03%) [3][6]. - Conversely, stocks such as *ST Suwu, Borui Pharmaceutical, and Haishike saw declines of 4.78%, 2.48%, and 2.18% respectively [1][9]. Group 2: Capital Inflow - The generic drug consistency evaluation sector attracted a net inflow of 584 million yuan, with 58 stocks receiving capital inflow, and 5 stocks exceeding 50 million yuan in net inflow [2]. - Leading the net inflow was Huahai Pharmaceutical with 266 million yuan, followed by Qianhong Pharmaceutical (201 million yuan) and Beilu Pharmaceutical (104 million yuan) [2][3]. Group 3: Capital Flow Ratios - Stocks such as Anglikang, Wantong Pharmaceutical, and Beilu Pharmaceutical had the highest net inflow ratios at 23.94%, 22.75%, and 15.95% respectively [3]. - Huahai Pharmaceutical recorded a daily turnover rate of 7.71% with a net inflow ratio of 12.53% [3].

Group 1 - The A-share innovative drug sector experienced a significant surge in the afternoon, with notable stocks such as Shutai Shen and Guanhao Bio hitting the 20% daily limit increase [1] - Nuo Si Lan De saw a substantial rise of 18%, while Warner Pharmaceuticals increased by over 17% [1] - Other companies like Ruizhi Medicine and Beilu Pharmaceutical also followed the upward trend [1]

Financial Performance - In Q1 2025, Beilu Pharmaceutical achieved operating revenue of 28,268.07 million yuan, a year-on-year increase of 36.23% [2] - The net profit attributable to shareholders increased by 26.13%, amounting to 1,308.80 million yuan, while the net profit excluding non-recurring gains and losses rose by 14.34% [2] Business Growth Drivers - The growth in Q1 2025 was primarily driven by three core segments: chemical generic drugs, traditional Chinese medicine, and overseas markets [3] - The acquisition of Tianyuan Pharmaceutical has led to significant integration efforts, enhancing marketing strategies and operational efficiency [3] Market Expansion - The company plans to leverage EU and Brazil GMP certifications to accelerate market development in these regions, aiming to enhance international brand influence and market share [4][5] - In Q1 2025, the subsidiary Haichang Pharmaceutical's iodinated contrast agent received approval for sale in South Korea, and the iodinated injection was approved in the EU [4] Financial Structure - The debt ratio reached 42.49% in Q1 2025, an increase attributed to a new long-term loan of 160 million yuan for acquiring 80% of Tianyuan Pharmaceutical [4] - Future plans include optimizing the capital structure and reducing the debt ratio through diversified financing channels [4] Subsidiary Developments - The company has established several wholly-owned subsidiaries, including: - Beijing Aipai Kesi Pharmaceutical R&D Co., focusing on product development and technological upgrades [5] - Anhui Luying Pharmaceutical Co., assisting in operations at the Bozhou production base [5] - Hong Kong Yuan Zhi Pharmaceutical Co., serving as an overseas window for market expansion [5] Product and Market Strategy - The company is actively promoting the Jiuwei Zhenxin Granules to enhance market share, despite stable procurement prices for key ingredients [5] - The company has not yet entered the veterinary medicine sector, focusing instead on prescription drugs [7]